4B Technologies, a Suzhou biotech, signed a collaboration agreement with Hong Kong 's Insilico, an AI discovery company, to develop innovative small molecule therapies for amyotrophic lateral sclerosis and other major neurological diseases. 4B, which concentrates on novel CNS drugs, has already started Phase I trials of its lead asset for ALS and a rare condition. neuromyelitis optica. Using its knowledge of in neurosciences and CNS drug discovery, 4B has built a portfolio of five candidates for targets that include stroke and Alzheimer's in addition to ALS. More details.... Share this with colleagues: // //